Title : Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications.

Pub. Date : 2022 May 21

PMID : 35610089






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, defined-composition, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells. lisocabtagene maraleucel nuclear receptor subfamily 1 group I member 3 Homo sapiens
2 Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, defined-composition, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells. lisocabtagene maraleucel nuclear receptor subfamily 1 group I member 3 Homo sapiens